Dual-Chamber v. Single-Chamber Pacemaker Use Debated At NASPE
This article was originally published in The Gray Sheet
Executive Summary
Anticipated results from two early stage studies - the Mode Selection Trial (MOST) and the PAGE trial in the UK - will further support evidence to date that use of dual-chamber pacemakers is unnecessary in the majority of patients, according to Ronald Vliestra, MD, Watson Clinic, Lakeland, Florida.
You may also be interested in...
Dual-Chamber Pacers Help Reduce Thromboembolic Event Risk - AHA Study
Use of dual-chamber in lieu of single-chamber pacemakers for ventricular pacing can lower platelet activation in the heart and reduce the risk of thromboembolic events, William Toff, MD, University of Leicester (UK) told attendees of the American Heart Association's scientific sessions Nov. 10 in Atlanta.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.